{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:46:43Z","timestamp":1790520403652,"version":"4.1.0"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T00:00:00Z","timestamp":1673049600000},"content-version":"vor","delay-in-days":98,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T00:00:00Z","timestamp":1657497600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative 2 Joint Undertaking","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"name":"International Psoriasis Council"},{"name":"NIHR Biomedical Research Centre (BRC) at King\u2019s College London"},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Identification of those at risk of more severe psoriasis and\/or associated morbidities offers opportunity for early intervention, reduced disease burden and more cost-effective healthcare. Prognostic biomarkers of disease progression have thus been the focus of intense research, but none are part of routine practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To identify and catalogue candidate biomarkers of disease progression in psoriasis for the translational research community.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search of CENTRAL, Embase, LILACS and MEDLINE was performed for relevant articles published between 1990 and December 2021. Eligibility criteria were studies involving patients with psoriasis (any age, n \u2265 50) reporting biomarkers associated with disease progression. The main outcomes were any measure of skin severity or any prespecified psoriasis comorbidity. Data were extracted by one reviewer and checked by a second; studies meeting minimal quality criteria (longitudinal design and\/or use of methods to control for confounding) were formally assessed for bias. Candidate biomarkers were identified by an expert multistakeholder group using a majority voting consensus exercise, and mapped to relevant cellular and molecular pathways.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 181 included studies, most investigated genomic or proteomic biomarkers associated with disease severity (n = 145) or psoriatic arthritis (n = 30). Methodological and reporting limitations compromised interpretation of findings, most notably a lack of longitudinal studies, and inadequate control for key prognostic factors. The following candidate biomarkers with future potential utility were identified for predicting disease severity: LCE3D, interleukin (IL)23R, IL23A, NFKBIL1 loci, HLA-C*06:02 (genomic), IL-17A, IgG aHDL, GlycA, I-FABP and kallikrein 8 (proteomic), tyramine (metabolomic); psoriatic arthritis: HLA-C*06:02, HLA-B*27, HLA-B*38, HLA-B*08, and variation at the IL23R and IL13 loci (genomic); IL-17A, CXCL10, Mac-2 binding protein, integrin b5, matrix metalloproteinase-3 and macrophage-colony stimulating factor (proteomic) and tyramine and mucic acid (metabolomic); and type 2 diabetes mellitus: variation in IL12B and IL23R loci (genomic). No biomarkers were supported by sufficient evidence for clinical use without further validation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This review provides a comprehensive catalogue of investigated biomarkers of disease progression in psoriasis. Future studies must address the common methodological limitations identified herein to expedite discovery and validation of biomarkers for clinical use.<\/jats:p>\n                    <jats:p>What is already known about this topic? \u00a0The current treatment paradigm in psoriasis is reactive.There is a need to develop effective risk-stratified management approaches that can proactively attenuate the substantial burden of disease.Prognostic biomarkers of disease progression have therefore been the focus of intense research.<\/jats:p>\n                    <jats:p>What does this study add? \u00a0This review is the first to scope, collate and catalogue research investigating biomarkers of disease progression in psoriasis.The review identifies potentially promising candidate biomarkers for further investigation and highlights common important limitations that should be considered when designing and conducting future studies in this area.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bjd.21627","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T13:24:49Z","timestamp":1651152289000},"page":"481-493","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Biomarkers of disease progression in people with psoriasis: a scoping review"],"prefix":"10.1093","volume":"187","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4599-9455","authenticated-orcid":false,"given":"Ravi","family":"Ramessur","sequence":"first","affiliation":[{"name":"St John\u2019s Institute of Dermatology, School of Basic & Medical Biosciences and Department of Medical & Molecular Genetics, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine King\u2019s College London London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Corbett","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination University of York York UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Marshall","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination University of York York UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8278-240X","authenticated-orcid":false,"given":"Marcio L.","family":"Acencio","sequence":"additional","affiliation":[{"name":"Luxembourg Centre for Systems Biomedicine University of Luxembourg Esch-sur-Alzette Luxembourg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines A.","family":"Barbosa","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, School of Basic & Medical Biosciences and Department of Medical & Molecular Genetics, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine King\u2019s College London London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1805-6278","authenticated-orcid":false,"given":"Nick","family":"Dand","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, School of Basic & Medical Biosciences and Department of Medical & Molecular Genetics, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine King\u2019s College London London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2066-7780","authenticated-orcid":false,"given":"Paola","family":"Di Meglio","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, School of Basic & Medical Biosciences and Department of Medical & Molecular Genetics, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine King\u2019s College London London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma","family":"Haddad","sequence":"additional","affiliation":[{"name":"University College Hospital NHS Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2589-8676","authenticated-orcid":false,"given":"Andreas H.M.","family":"Jensen","sequence":"additional","affiliation":[{"name":"University of Copenhagen Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Witte","family":"Koopmann","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine LEO Pharma A\/S Ballerup Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satveer K.","family":"Mahil","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, School of Basic & Medical Biosciences and Department of Medical & Molecular Genetics, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine King\u2019s College London London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Ostaszewski","sequence":"additional","affiliation":[{"name":"Luxembourg Centre for Systems Biomedicine University of Luxembourg Esch-sur-Alzette Luxembourg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5106-4237","authenticated-orcid":false,"given":"Seher","family":"Rahmatulla","sequence":"additional","affiliation":[{"name":"West Hertfordshire NHS Trust Hertfordshire UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Rastrick","sequence":"additional","affiliation":[{"name":"Department of Immunology Research UCB Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake","family":"Saklatvala","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, School of Basic & Medical Biosciences and Department of Medical & Molecular Genetics, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine King\u2019s College London London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3944-252X","authenticated-orcid":false,"given":"Stephan","family":"Weidinger","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy University Hospital Schleswig-Holstein Kiel Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kath","family":"Wright","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination University of York York UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kilian","family":"Eyerich","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy Technical University of Munich Munich Germany"},{"name":"Division of Dermatology, Department of Medicine Karolinska Insitutet Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matladi","family":"Ndlovu","sequence":"additional","affiliation":[{"name":"Department of Immunology Research UCB Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan N.","family":"Barker","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, School of Basic & Medical Biosciences and Department of Medical & Molecular Genetics, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine King\u2019s College London London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4784-9680","authenticated-orcid":false,"given":"Lone","family":"Skov","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Department of Clinical Medicine University of Copenhagen Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curdin","family":"Conrad","sequence":"additional","affiliation":[{"name":"Department of Dermatology Lausanne University Hospital CHUV & University of Lausanne Lausanne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine H","family":"Smith","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, School of Basic & Medical Biosciences and Department of Medical & Molecular Genetics, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine King\u2019s College London London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the BIOMAP consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,1]]},"reference":[{"key":"2023010808114851300_bjd21627-bib-0001","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"2023010808114851300_bjd21627-bib-0002","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"2023010808114851300_bjd21627-bib-0003","doi-asserted-by":"crossref","first-page":"adv00030","DOI":"10.2340\/00015555-3384","article-title":"Psoriasis and genetics","volume":"100","author":"Dand","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"2023010808114851300_bjd21627-bib-0004","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/jid.2010.103","article-title":"Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions","volume":"130","author":"Davidovici","year":"2010","journal-title":"J Invest Dermatol"},{"key":"2023010808114851300_bjd21627-bib-0005","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and management of rheumatoid arthritis: a review","volume":"320","author":"Aletaha","year":"2018","journal-title":"JAMA"},{"key":"2023010808114851300_bjd21627-bib-0006","volume-title":"BEST (Biomarkers, EndpointS, and other Tools) Resource","author":"FDA-NIH Biomarker Working Group","year":"2016"},{"key":"2023010808114851300_bjd21627-bib-0007","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.jaci.2017.10.003","article-title":"Biomarkers in connective tissue diseases","volume":"140","author":"Jog","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"2023010808114851300_bjd21627-bib-0008","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/COH.0b013e32833ed177","article-title":"What are biomarkers?","volume":"5","author":"Strimbu","year":"2010","journal-title":"Curr Opin HIV AIDS"},{"key":"2023010808114851300_bjd21627-bib-0009","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12874-018-0583-x","article-title":"Development and reliability assessment of a new quality appraisal tool for cross-sectional studies using biomarker data (BIOCROSS)","volume":"18","author":"Wirsching","year":"2018","journal-title":"BMC Med Res Methodol"},{"key":"2023010808114851300_bjd21627-bib-0010","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann Intern Med"},{"key":"2023010808114851300_bjd21627-bib-0011","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s13671-012-0034-6","article-title":"Risk Factors for Psoriasis","volume":"2","author":"Naldi","year":"2013","journal-title":"Current Dermatology Reports"},{"key":"2023010808114851300_bjd21627-bib-0012","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1634\/theoncologist.2014-0061","article-title":"Biomarker validation: common data analysis concerns","volume":"19","author":"Ensor","year":"2014","journal-title":"Oncologist"},{"key":"2023010808114851300_bjd21627-bib-0013","doi-asserted-by":"crossref","first-page":"12754","DOI":"10.1038\/s41598-020-69537-3","article-title":"Metagenomic analysis of gut microbiota in non-treated plaque psoriasis patients stratified by disease severity: development of a new Psoriasis-Microbiome Index","volume":"10","author":"Dei-Cas","year":"2020","journal-title":"Sci Rep"},{"key":"2023010808114851300_bjd21627-bib-0014","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1038\/s41467-018-06672-6","article-title":"Genetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients","volume":"9","author":"Patrick","year":"2018","journal-title":"Nat Commun"},{"key":"2023010808114851300_bjd21627-bib-0015","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.ajhg.2015.10.019","article-title":"Genome-wide association analysis of psoriatic arthritis and cutaneous psoriasis reveals differences in their genetic architecture","volume":"97","author":"Stuart","year":"2015","journal-title":"Am J Hum Genet"},{"key":"2023010808114851300_bjd21627-bib-0016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0192010","article-title":"Genetic polymorphisms associated with psoriasis and development of psoriatic arthritis in patients with psoriasis","volume":"13","author":"Loft","year":"2018","journal-title":"PLOS ONE"},{"key":"2023010808114851300_bjd21627-bib-0017","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/bjd.18940","article-title":"Declining levels of serum chemokine (C-X-C motif) ligand 10 over time are associated with new onset of psoriatic arthritis in patients with psoriasis: a new biomarker?","volume":"183","author":"Abji","year":"2020","journal-title":"Br J Dermatol"},{"key":"2023010808114851300_bjd21627-bib-0018","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1002\/art.39800","article-title":"Brief report: CXCL10 is a possible biomarker for the development of psoriatic arthritis among patients with psoriasis","volume":"68","author":"Abji","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2023010808114851300_bjd21627-bib-0019","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13075-017-1417-7","article-title":"Serum bone-turnover biomarkers are associated with the occurrence of peripheral and axial arthritis in psoriatic disease: a prospective cross-sectional comparative study","volume":"19","author":"Jadon","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2023010808114851300_bjd21627-bib-0020","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2340\/00015555-0184","article-title":"Clinical associations of the risk alleles of HLA-Cw6 and CCHCR1*WWCC in psoriasis","volume":"87","author":"Suomela","year":"2007","journal-title":"Acta Derm Venereol"},{"key":"2023010808114851300_bjd21627-bib-0021","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/acr.23298","article-title":"Differentiating psoriatic arthritis from psoriasis without psoriatic arthritis using novel serum biomarkers","volume":"70","author":"Cretu","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2023010808114851300_bjd21627-bib-0022","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00281-015-0539-8","article-title":"Update on psoriasis immunopathogenesis and targeted immunotherapy","volume":"38","author":"Mahil","year":"2016","journal-title":"Semin Immunopathol"},{"key":"2023010808114851300_bjd21627-bib-0023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000606","article-title":"Multiple loci within the major histocompatibility complex confer risk of psoriasis","volume":"5","author":"Feng","year":"2009","journal-title":"PLOS Genet"},{"key":"2023010808114851300_bjd21627-bib-0024","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1046\/j.1365-2133.2003.05115.x","article-title":"Psoriasis patients who are homozygous for the HLA-Cw 0602 allele have a 2.5-fold increased risk of developing psoriasis compared with Cw6 heterozygotes","volume":"148","author":"Gudjonsson","year":"2003","journal-title":"Br J Dermatol"},{"key":"2023010808114851300_bjd21627-bib-0025","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1046\/j.0022-202x.2001.01656.x","article-title":"HLA-Cw6-positive and HLA-Cw6-negative patients with psoriasis vulgaris have distinct clinical features","volume":"118","author":"Gudjonsson","year":"2002","journal-title":"J Invest Dermatol"},{"key":"2023010808114851300_bjd21627-bib-0026","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1093\/hmg\/dds295","article-title":"Risk variants for psoriasis vulgaris in a large case-control collection and association with clinical subphenotypes","volume":"21","author":"Julia","year":"2012","journal-title":"Hum Mol Genet"},{"key":"2023010808114851300_bjd21627-bib-0027","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/sj.jid.5700118","article-title":"Distinct clinical differences between HLA-Cw 0602 positive and negative psoriasis patients--an analysis of 1019 HLA-C- and HLA-B-typed patients","volume":"126","author":"Gudjonsson","year":"2006","journal-title":"J Invest Dermatol"},{"key":"2023010808114851300_bjd21627-bib-0028","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1136\/ard.2011.155044","article-title":"Human leucocyte antigen risk alleles for psoriatic arthritis among patients with psoriasis","volume":"71","author":"Eder","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2023010808114851300_bjd21627-bib-0029","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.jid.2021.08.446","article-title":"Differences in clinical features and comorbid burden between HLA-C*06:02 carrier groups in &gt;9,000 people with psoriasis","volume":"142","author":"Douroudis","year":"2022","journal-title":"J Invest Dermatol"},{"key":"2023010808114851300_bjd21627-bib-0030","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1136\/annrheumdis-2017-211414","article-title":"Cross-phenotype association mapping of the MHC identifies genetic variants that differentiate psoriatic arthritis from psoriasis","volume":"76","author":"Bowes","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023010808114851300_bjd21627-bib-0031","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jdermsci.2014.05.010","article-title":"Genetic variation at IL12B, IL23R and IL23A is associated with psoriasis severity, psoriatic arthritis and type 2 diabetes mellitus","volume":"75","author":"Eiris","year":"2014","journal-title":"J Dermatol Sci"},{"key":"2023010808114851300_bjd21627-bib-0032","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1038\/jid.2015.103","article-title":"Association with genetic variants in the IL-23 and NF-\u03baB pathways discriminates between mild and severe psoriasis skin disease","volume":"135","author":"Nikamo","year":"2015","journal-title":"J Invest Dermatol"},{"key":"2023010808114851300_bjd21627-bib-0033","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s12026-013-8384-0","article-title":"C-reactive protein and the biology of disease","volume":"56","author":"Ansar","year":"2013","journal-title":"Immunol Res"},{"key":"2023010808114851300_bjd21627-bib-0034","first-page":"894","article-title":"High macrophage-colony stimulating factor levels in synovial fluid of loose artificial hip joints","volume":"27","author":"Takei","year":"2000","journal-title":"J Rheumatol"},{"key":"2023010808114851300_bjd21627-bib-0035","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/964131","article-title":"Matrix metalloproteinases in inflammatory bowel disease: an update","volume":"2015","author":"O\u2019Sullivan","year":"2015","journal-title":"Mediators Inflamm"},{"issue":"Suppl. B","key":"2023010808114851300_bjd21627-bib-0036","doi-asserted-by":"crossref","first-page":"25b","DOI":"10.1016\/S0828-282X(06)70983-7","article-title":"Matrix metalloproteinases in cardiovascular disease","volume":"22","author":"Liu","year":"2006","journal-title":"Can J Cardiol"},{"key":"2023010808114851300_bjd21627-bib-0037","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41584-018-0005-9","article-title":"Biomarkers as drug development tools: discovery, validation, qualification and use","volume":"14","author":"Kraus","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2023010808114851300_bjd21627-bib-0038","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/10408363.2020.1775545","article-title":"Multiple biomarker approach for the diagnosis and therapy of rheumatoid arthritis","volume":"58","author":"Savvateeva","year":"2021","journal-title":"Crit Rev Clin Lab Sci"},{"key":"2023010808114851300_bjd21627-bib-0039","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s13075-020-02355-0","article-title":"Derivation and internal validation of a multi-biomarker-based cardiovascular disease risk prediction score for rheumatoid arthritis patients","volume":"22","author":"Curtis","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2023010808114851300_bjd21627-bib-0040","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1136\/ard.2010.147421","article-title":"IL13 gene polymorphism is a marker for psoriatic arthritis among psoriasis patients","volume":"70","author":"Eder","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2023010808114851300_bjd21627-bib-0041","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00403-019-01986-x","article-title":"Antibodies towards high-density lipoprotein components in patients with psoriasis","volume":"312","author":"Paiva-Lopes","year":"2020","journal-title":"Arch Dermatol Res"},{"key":"2023010808114851300_bjd21627-bib-0042","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1161\/CIRCRESAHA.116.309637","article-title":"GlycA is a novel biomarker of inflammation and subclinical cardiovascular disease in psoriasis","volume":"119","author":"Joshi","year":"2016","journal-title":"Circ Res"},{"key":"2023010808114851300_bjd21627-bib-0043","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3390\/jcm8071021","article-title":"Intestinal fatty acid binding protein, a biomarker of intestinal barrier, is associated with severity of psoriasis","volume":"8","author":"Sikora","year":"2019","journal-title":"J Clin Med"},{"key":"2023010808114851300_bjd21627-bib-0044","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1515\/cclm-2012-0251","article-title":"Serum kallikrein-8 correlates with skin activity, but not psoriatic arthritis, in patients with psoriatic disease","volume":"51","author":"Eissa","year":"2013","journal-title":"Clin Chem Lab Med"},{"key":"2023010808114851300_bjd21627-bib-0045","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/rheumatology\/keq105","article-title":"Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis","volume":"49","author":"Chandran","year":"2010","journal-title":"Rheumatology"},{"key":"2023010808114851300_bjd21627-bib-0046","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jdermsci.2021.03.006","article-title":"Large-scale plasma-metabolome analysis identifies potential biomarkers of psoriasis and its clinical subtypes","volume":"102","author":"Kishikawa","year":"2021","journal-title":"J Dermatol Sci"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjd.21627","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjd.21627","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/187\/4\/481\/48529411\/bjd0481.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/187\/4\/481\/48529411\/bjd0481.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T09:12:56Z","timestamp":1676365976000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/187\/4\/481\/6966266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,1]]},"references-count":46,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,10,1]]},"published-print":{"date-parts":[[2022,10,1]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.21627","relation":{},"ISSN":["1365-2133","0007-0963"],"issn-type":[{"value":"1365-2133","type":"electronic"},{"value":"0007-0963","type":"print"}],"subject":[],"published-other":{"date-parts":[[2022,10,1]]},"published":{"date-parts":[[2022,10,1]]},"assertion":[{"value":"2021-07-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}